The Community Effectiveness of IPTi in Southern Tanzania

Summary

The safety and efficacy of Intermittent Preventive Treatment for malaria and anaemia control in Infants (IPTi) have already been documented in Southern Tanzania, affording an opportunity to gain operational experience in developing a strategy for the longer-term implementation of IPTi. Working in conjunction with national and district-based health authorities, a strategy will be developed to make IPTi available through routine health services and an effectiveness evaluation conducted. This will be based on the comparison of process and outcome indicators in areas with and without IPTi. Information on safety will be consolidated and the effect of IPTi on the rate of development of drug resistance explored. The acceptability and costs of implementing IPTi will be monitored and combined with assessments of effectiveness (in terms of morbidity and mortality) to assess the cost-effectiveness of IPTi.

Conditions

• Malaria, Falciparum
• Anemia

Interventions

DRUG

Sulfadoxine-pyrimethamine used for IPTi

Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination

DRUG

IPTi

Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination

Sponsors & Collaborators

• Ifakara Health Research and Development Centre

  collaborator OTHER

• Ministry of Health, Tanzania

  collaborator OTHER_GOV

• Hospital Clinic of Barcelona

  collaborator OTHER

• London School of Hygiene and Tropical Medicine

  collaborator OTHER

• Swiss Tropical & Public Health Institute

  lead OTHER

Principal Investigators

• David M Schellenberg, MRCP PhD · London School of Hygiene & Tropical Medicine, London, UK/Ifakara Health Research & Development Centre, Tanzania

• Hassan Mshinda, PhD · Ifakara Health Research & Development Centre, Tanzania

• Joanna RM Armstrong Schellenberg, PhD · London School of Hygiene & Tropical Medicine, London, UK/Ifakara Health Research & Development Centre, Tanzania

• Pedro L Alonso, MD PhD · Hospital Clinic, Barcelona, Spain

• Marcel Tanner, PhD · Swiss Tropical Institute, Basle, Switzerland

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2005-03-31

Primary Completion

2007-12-31

Completion

2008-12-31

Countries

• Tanzania

Study Locations